QNCX
Quince Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Quince Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
No changes.
No changes.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Annual filing, covered
10-K parsed · Apr 10 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Apr 10 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Quince Therapeutics, Inc.
33.00
−0.55 · −1.64%
post 33.00 0.00%
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Quince Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Quince Therapeutics, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| Tudor Investment Corp ET AL | $4.2M | 37.72% | +6.18% |
| Ikarian Capital | $1.3M | 11.67% | new |
| Millennium | $1.3M | 11.43% | new |
| Balyasny | $1.3M | 11.30% | new |
| Susquehanna International | $1.0M | 8.88% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Tudor Investment Corp ET AL | $4.2M | 37.72% | +6.18% |
| Ikarian Capital | $1.3M | 11.67% | new |
| Millennium | $1.3M | 11.43% | new |
| Balyasny | $1.3M | 11.30% | new |
| Susquehanna International | $1.0M | 8.88% | new |